Innovating the next generation of immunological therapeutics


The Swedish National Innovation Agency grants further funding to develop the Tailored Leukapheresis Treatment (TLA) for Immune Mediated Inflammatory Diseases (IMIDs).

VINNOVA Grants Further Development of TLA

The funding decision was announced during the fall 2013 to support clinical research for investigating in vivo feasibility of using the novel TLA treatment for the selected (IMIDs): Rheumatoid Arthritis, Multiple Sclerosis, Amytrophic Lateral Sclerosis, Primary Sclerosing Cholangitis and Alcohol Hepatitis. Karolinska Institute will lead the research consortium involving an integrated and interdisciplinary team of clinicians, research scientists and pharmaceutical market economists.